Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center

Olivier Riou; Pascal Fenoglietto; Benoit Laliberté; Cathy Menkarios; Carmen Llacer Moscardo; Meng Huor Hay; Norbert Ailleres; Jean-Bernard Dubois; Xavier Rebillard; David Azria

doi:10.5402/2012/391705

Retour

Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center

Article de revue

Avec comité de lecture

Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center

Olivier Riou, Pascal Fenoglietto, Benoit Laliberté, Cathy Menkarios, Carmen Llacer Moscardo, Meng Huor Hay, Norbert Ailleres, Jean-Bernard Dubois, Xavier Rebillard et David Azria

ISRN urology, Vol.2012(2012), pp.1-7

2012

DOI: https://doi.org/10.5402/2012/391705

PMID: 22567417

Résumé

Clinical Study

Background. To assess the feasibility of salvage intensity-modulated radiation Therapy (IMRT) and to examine clinical outcome. Patients and Methods. 57 patients were treated with salvage IMRT to the prostate bed in our center from January, 2007, to February, 2010. The mean prescription dose was 68 Gy in 34 fractions. Forty-four patients received concomitant androgen deprivation. Results. Doses to organs at risk were low without altering target volume coverage. Salvage IMRT was feasible without any grade 3 or 4 acute gastrointestinal or urinary toxicity. With a median follow-up of 21 months, one grade 2 urinary and 1 grade ≥2 rectal late toxicities were reported. Biological relapse-free survival was 96.5% (2.3% (1/44) relapsed with androgen suppression and 7.7% (1/13) without). Conclusion. Salvage IMRT is feasible and results in low acute and chronic side-effects. Longer follow-up is warranted to draw conclusions in terms of oncologic control.

Indicateurs

1 Consultations de la notice

Détails

Titre: Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center
Créateurs - sans rôle: Olivier Riou - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Pascal Fenoglietto - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Benoit Laliberté - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Cathy Menkarios - Hôpital Maisonneuve-Rosemont
Carmen Llacer Moscardo - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Meng Huor Hay - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Norbert Ailleres - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Jean-Bernard Dubois - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Xavier Rebillard - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
David Azria - Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier 34298, France Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada H1T 2M4 Department of Urology, Clinique Beausoleil, Montpellier 34070, France
Détails de publication: ISRN urology, Vol.2012(2012), pp.1-7
Éditeur: International Scholarly Research Network
Identifiants: 99140077609311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article